Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of... | March 24, 2022

Related Keywords

China ,Roger Adsett ,Landos Biopharma ,Wilkinson Brimmer Katcher ,Chris Garabedian ,Tim Mayleben ,Joele Frank ,Exchange Commission ,Development Expenses ,Clinical Development Updates ,Landos Biopharma Inc ,Progress Towards Optimizing Clinical Development ,Nasdaq ,Initiate Phase ,Ulcerative Colitis Later ,Ulcerative Colitis ,Normal Healthy Volunteers ,Top Line Results ,Both Studies Expected ,Interim President ,Landos Board ,Fourth Quarter ,Full Year ,Cash Equivalents ,Marketable Securities ,Administrative Expenses ,Annual Reports ,Quarterly Reports ,Tanner Kaufman ,Wilkinson Brimmer ,Consolidated Statements ,Ended December ,Convertible Preferred Stock ,Stockholder Equity ,Nc Stock Exchange ,News ,Information ,Press Release ,Ontinued ,Progress ,Cowards ,Optimizing ,Linical ,Development ,Plans ,N ,Track ,O ,Nitiate ,Hase ,Tb ,Study ,F ,Ulcerative ,Colitis ,Water ,This ,Ear ,Ompleted ,Enrollment ,Rial Labp Us5150691021 ,